Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Catalyst (CPRX) Up on New Drug Application for Firdapse

by Zacks Equity Research

Catalyst (CPRX) new drug application for its lead pipeline candidate keeps it on a growth trajectory.

    Zacks Equity Research

    Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress

    by Zacks Equity Research

    Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.

      Zacks Equity Research

      What's in Store for Catalyst (CPRX) This Earnings Season?

      by Zacks Equity Research

      Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.

        Zacks Equity Research

        Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling

        by Zacks Equity Research

        Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.

          Zacks Equity Research

          What Drives Catalyst Pharmaceuticals Above 250% This Year?

          by Zacks Equity Research

          We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.

            Zacks Equity Research

            Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

            by Zacks Equity Research

            Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

              Zacks Equity Research

              Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

              by Zacks Equity Research

              Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

                Zacks Equity Research

                Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

                by Zacks Equity Research

                Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

                  Zacks Equity Research

                  What's in Store for Catalyst (CPRX) This Earnings Season?

                  by Zacks Equity Research

                  Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

                    Zacks Equity Research

                    Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

                    by Zacks Equity Research

                    : Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.